drugset / Trial / NCT06841445

Efficacy and Safety of HRS9531 Tablet in Obese Subjects

NCT06841445

Phase 2 Completed 166 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy of HRS9531 tablet compared with placebo in reducing body weight in obese subjects after 26 weeks of treatment.

Timeline

Start
2025-04-07
Primary completion
2026-01-08
Completion
2026-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown

Indications

No indication recorded.